格隆汇2月27日丨振东制药(300158.SZ)公布，截至2026年2月27日，公司第四期员工持股计划尚未购买 公司股票。 ...

根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》的相关要求，现将公司第四期员工持股计划实施进展情况公告 如下： 截至 2026 年 2 月 27 日，公司第四期员工持股计划尚未购买公司股 票。 山西振东制药股份有限公司 关于第四期员工持股计划实施进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"）于 2025 年 11 月 19 日召开第六届董事会第八次会议及第六届监事会第六次会议、2025 年 12 月 18 日召开 2025 年第二次临时股东大会，会议审议通过了《关于< 山西振东制药股份有限公司第四期员工持股计划（草案）>及其摘要的 议案》《关于<山西振东制药股份有限公司第四期员工持股计划管理办 法>的议案》及其他相关议案。相关具体内容详见公司于 2025 年 11 月 20 日、2025 年 12 月 18 日在巨潮咨询网（http://www.cninfo.com.cn）披 露的相关公告。 证券代码：300158 证 ...

财报分析 2025年三季报显示，振东制药前三季度营业收入22.15亿元，同比减少2.42%；归母净利润2036.41万 元，同比下降49.25%；但扣非净利润50.75万元，同比上升101.67%，第三季度单季归母净利润同比增长 31.34%。公司主营业务中中药占比54.82%，化药占比43.10%。 经济观察网 2026年2月12日，工业和信息化部等八部门印发《中药工业高质量发展实施方案（2026— 2030年）》，明确到2030年培育60个高标准中药原料生产基地、建设5个中药工业守正创新中心等目 标，为中药企业带来政策利好。此外，2026年2月2日至5日，振东制药（300158）联合山西中医药大学 赴澳大利亚进行学术交流，与悉尼大学、阿德莱德大学续签合作备忘录，深化中医药科研国际化布局。 股票近期走势 截至2026年2月12日收盘，振东制药股价报6.13元，单日下跌2.70%，近5日累计上涨6.79%；成交额2.51 亿元，换手率4.11%。资金流向方面，2月12日主力资金净流出3822.50万元，而2月9日曾出现主力净流 入2301.98万元的情况，显示短期资金波动较大。 机构观点 湘财证券2026年2 ...

Core Viewpoint - The recent surge in the stock price of Zhen Dong Pharmaceutical is attributed to significant advancements in innovative drug development, product pipeline implementation, and corporate governance optimization, which are gaining recognition in the capital market [1][4]. Group 1: Innovative Drug Development - Zhen Dong Pharmaceutical's subsidiary, Zhen Dong Anxin Biotech, received formal acceptance from the National Medical Products Administration for its finasteride tablet generic drug application, targeting common conditions such as androgenetic alopecia and benign prostatic hyperplasia, enhancing the company's position in the hair health sector [1]. - The company achieved a milestone in gynecological innovative drugs with the acceptance of its new drug application for a vaginal probiotic capsule, which utilizes an innovative mechanism to restore vaginal microecology, showing superior cure rates and safety compared to traditional antibiotics [2]. - Ongoing research in oncology includes projects for gastric cancer (ZD09), breast cancer bone metastasis (ZDH02), and atopic dermatitis (SH003), alongside a newly introduced epinephrine nasal spray for out-of-hospital intervention in allergic shock, which has secured core patents in Europe and the US [2]. Group 2: Consumer Health and Brand Development - Zhen Dong Pharmaceutical is actively promoting its "Dafeixin" brand through social media platforms and partnerships with chain pharmacies, achieving a 31.34% year-on-year increase in net profit to 12.43 million yuan in Q3 2025, reflecting the profitability of its high-value products [3]. - The company has also received approval for the "Dafeixin" cypress leaf anti-hair loss shampoo, further expanding its product matrix in hair health [3]. Group 3: Corporate Governance and Structural Improvements - The company is enhancing its governance by implementing cumulative voting in board elections to protect minority shareholders' rights and improve decision-making processes [3]. - Recent share purchases by board member Lei Zhenhong demonstrate confidence in the company's long-term value, with an acquisition of 1,600 shares at an average price of 5.99 yuan per share [3]. Group 4: Strategic Transformation - Zhen Dong Pharmaceutical is transitioning from a traditional "generic + Chinese herbal medicine" model to a dual-engine strategy focused on "innovative drugs + consumer health," laying a solid foundation for long-term development and high-quality growth [4].

文 | 张阳阳 下跌个股中，锦波生物、北方铜业、美锦能源等7只个股跌幅均在1%以上；山煤国际、山西焦化、山西 焦煤等13只个股跌幅收窄在1%以内。 山西板块今日整体表现稳健，指数上涨0.54%，成交额为138.66亿元，反映出市场情绪积极且资金参与 度较高。 涨跌情况方面，山西板块41只个股，19只上涨，20只下跌，2只平盘。 上涨个股中，领涨股振东制药显著上涨，涨幅达到13.24%；晋控电力同样上涨明显，涨幅为9.97%。 此外，仟源医药上涨4.43%；蓝焰控股、科新发展涨逾2%；潞化科技、永东股份、东杰智能涨超1%； 国新能源、金利华电、华阳股份等11只个股涨幅均在1%以下。 2月6日，A股三大指数集体下跌，截至收盘，上证指数跌0.25%，深证成指跌0.33%，创业板指跌 0.73%；北证50涨0.9%。沪深两市成交额约21457.19亿元，较前一个交易日缩量约305亿元。 ...

Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Industry Overview - The gynecological medication industry encompasses drugs for the prevention, diagnosis, and treatment of gynecological diseases, including traditional hormone therapies, antibiotics, analgesics, and immunomodulators [1][3] - The market for gynecological medications in China has shown rapid growth, with the market size increasing from 27.735 billion yuan in 2012 to an estimated 56.137 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 6.05% [1][9] - By 2025, the market size is projected to reach approximately 59.53 billion yuan, driven by increasing awareness of women's health and societal emphasis on female health [1][9] Market Dynamics - The prevalence of gynecological diseases among adult women in China is high, with an estimated incidence rate between 40% and 70%, including conditions such as tumors, cysts, reproductive-related diseases, and gynecological inflammation [6] - The rise in gynecological disease rates and the growing health consciousness among women are contributing to the steady expansion of the gynecological medication market [6] Industry Chain - The gynecological medication industry chain consists of upstream raw materials, intermediates, and pharmaceutical equipment; midstream production; and downstream distribution through pharmacies, hospitals, and e-commerce platforms [6][7] Key Companies - Notable companies in the gynecological medication sector include Qianjin Pharmaceutical, Tongrentang, Kangyuan Pharmaceutical, Jiuzhitang, Yunnan Baiyao, and others, which are focusing on R&D and product differentiation [10][11] Development Trends - Future product development in gynecological medications is expected to shift towards precision and individualized treatment, utilizing diagnostic technologies to enhance treatment efficacy and reduce side effects [12] - Innovations in drug formulations and delivery methods will improve patient compliance and experience, with a focus on long-acting, user-friendly options [13] - The role of gynecological medication companies is evolving from mere drug suppliers to providers of comprehensive health management solutions for women throughout their life stages [14]

证券代码：300158 证券简称：振东制药 公告编号：2026-002 山西振东制药股份有限公司 关于第四期员工持股计划实施进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"）于 2025 年 11 月 19 日召开第六届董事会第八次会议及第六届监事会第六次会议、2025 年 12 月 18 日召开 2025 年第二次临时股东大会，会议审议通过了《关于< 山西振东制药股份有限公司第四期员工持股计划（草案）>及其摘要的 议案》《关于<山西振东制药股份有限公司第四期员工持股计划管理办 法>的议案》及其他相关议案。相关具体内容详见公司于 2025 年 11 月 20 日、2025 年 12 月 18 日在巨潮咨询网（http://www.cninfo.com.cn）披 露的相关公告。 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》的相关要求，现将公司第四期员工持股计划实施进展情况公告 如下： 1、公司第四期员工持股计划已在中国证 ...

证券代码：300158 证券简称：振东制药 公告编号：2026-003 山西振东制药股份有限公司 第四期员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、持有人会议召开情况 山西振东制药股份有限公司（以下简称"公司"）第四期员工持股 计划（以下简称"本次员工持股计划"）第一次持有人会议于 2026 年1月29日上午9:00在公司会议室通过现场结合通讯表决方式召开， 会议通知于 2026 年 1 月 23 日以电话、邮件等方式通知全体持有人。 本次会议由公司董事长李昆先生召集和主持。本次会议实际参加表决 的持有人共计 368 人，代表本次员工持股计划份额 206,750,000 份， 占本次员工持股计划份额总数的 82.70%。 本次会议的召集、召开和表决程序符合相关法律法规和《山西振 东制药股份有限公司第四期员工持股计划》、《山西振东制药股份有 限公司第四期员工持股计划管理办法》的相关规定。 二、持有人会议审议情况 经与会持有人审议，会议通过了以下议案： 1、审议通过《关于设立公司第四期员工持股计划管理委员会的 议案》。 ...

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].